Evidence map›Paper›PMID 34610973›Full record

ArticleLife science alliance2021

Suppression of isoprenylcysteine carboxylmethyltransferase compromises DNA damage repair.

Jingyi Tang, Patrick J Casey, Mei Wang

Open access · goldAbstract read
In one paragraph

Article in Life science alliance, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Jingyi TangDuke-NUS Medical School, Program in Cancer and Stem Cell, Singapore, Singapore.
Patrick J CaseyDuke-NUS Medical School, Program in Cancer and Stem Cell, Singapore, Singapore.ORCID 0000-0002-7366-9309
Mei WangDuke-NUS Medical School, Program in Cancer and Stem Cell, Singapore, Singapore mei.wang@duke-nus.edu.sg.ORCID 0000-0001-6887-6840
Duke-NUS Medical School · SGDuke University · USNational University of Singapore · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

DNA damage is a double-edged sword for cancer cells. On the one hand, DNA damage-induced genomic instability contributes to cancer development; on the other hand, accumulating damage compromises proliferation and survival of cancer cells. Understanding the key regulators of DNA damage repair machinery would benefit the development of cancer therapies that induce DNA damage and apoptosis. In this study, we found that isoprenylcysteine carboxylmethyltransferase (ICMT), a posttranslational modification enzyme, plays an important role in DNA damage repair. We found that ICMT suppression consistently reduces the activity of MAPK signaling, which compromises the expression of key proteins in the DNA damage repair machinery. The ensuing accumulation of DNA damage leads to cell cycle arrest and apoptosis in multiple breast cancer cells. Interestingly, these observations are more pronounced in cells grown under anchorage-independent conditions or grown in vivo. Consistent with the negative impact on DNA repair, ICMT inhibition transforms the cancer cells into a "BRCA-like" state, hence sensitizing cancer cells to the treatment of PARP inhibitor and other DNA damage-inducing agents.

Indexed as

AnimalsApoptosisBenzamidesBreast NeoplasmsCell Cycle CheckpointsCell Line, TumorCell ProliferationDNA DamageDNA RepairFemaleGenetic VectorsHEK293 CellsHumansIndazolesMAP Kinase Signaling SystemMice2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamideBenzamidesICMT protein, humanIndazolesniraparibPARP1 protein, humanPiperidinesPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsProtein MethyltransferasesRibonucleosidesRNA, Small Interferingtriciribine

Identifiers

PMID34610973
PMCPMC8500237
OpenAlexW3203081572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.